EGFR and non-small cell lung carcinoma: To investigate the roles of miR-19a in the development of TKI resistance in NSCLC, we first compared the serum expression of miR-19a in patients who initially harbored TKI-sensitive EGFR mutations to the serum level in the same individual after they had acquired resistance to gefitinib.